NEW YORK (GenomeWeb News) – Researchers at the Fraunhofer Institute in Germany are using Affymetrix’s Whole Transcript gene expression technology to develop a diagnostic test to detect drug-induced liver toxicity, the company said today.
Drug-induced liver toxicity is a common side effect of drug therapies and is “the most frequent reason why registered drugs are withdrawn from the market,” Affy said.
There is now “no reliable method to forecast the progression of various types of DILI,” and a tool that could be used to detect these could save around $2 billion per year in the US, Affy added.
The study is being led by professor Juergen Borlak, director of the Fraunhofer Institute of Toxicology and Experimental Medicine and head of the Institute of Pharmaco- and Toxicogenomics at the Hannover Medical School.
The Hannover Medical School is the largest liver transplant center in Europe, Affy said.
The company said the institute hopes to have a diagnostic tool ready for launch in the spring of 2009.
Financial terms of the agreement were not released.